Semaglutide 2 mg for type 2 diabetes
Record ID 32018005330
Authors' objectives: What is the clinical effectiveness of semaglutide subcutaneous injection 2 mg once weekly for the management of type 2 diabetes in adults? What is the cost-effectiveness of semaglutide subcutaneous injection 2 mg once weekly for the management of type 2 diabetes in adults?
Authors' results and conclusions: For patients with type 2 diabetes mellitus, a single randomized controlled trial (SUSTAIN FORTE) suggested that once-weekly subcutaneous semaglutide 2.0 mg may achieve better glycemic control than once-weekly subcutaneous semaglutide 1.0 mg. However, it is unclear whether between-group differences are clinically meaningful. Gastrointestinal disorders were the most common adverse event resulting in premature discontinuation in both groups. One participant in each study arm experienced a cardiovascular disorder serious enough for premature discontinuation. As most trial patients were white, it is unclear if the results are generalizable to groups with higher prevalence of T2DM in Canada, such as Indigenous peoples or those of South Asian descent. We did not find any studies on the cost-effectiveness of subcutaneous semaglutide 2.0 mg, compared to placebo or other doses of semaglutide.
Project Status: Completed
URL for project: https://www.cadth.ca/semaglutide-2-mg-type-2-diabetes
Year Published: 2023
URL for published report: https://www.cadth.ca/semaglutide-2-mg-type-2-diabetes
English language abstract: An English language summary is available
Publication Type: Rapid Review
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptides
- Hypoglycemic Agents
- Injections, Subcutaneous
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.